These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15705360)

  • 1. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.
    Zarate CA; Quiroz JA; Singh JB; Denicoff KD; De Jesus G; Luckenbaugh DA; Charney DS; Manji HK
    Biol Psychiatry; 2005 Feb; 57(4):430-2. PubMed ID: 15705360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole in the treatment of mood and anxiety disorders.
    Pittenger C; Coric V; Banasr M; Bloch M; Krystal JH; Sanacora G
    CNS Drugs; 2008; 22(9):761-86. PubMed ID: 18698875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.
    Sanacora G; Kendell SF; Levin Y; Simen AA; Fenton LR; Coric V; Krystal JH
    Biol Psychiatry; 2007 Mar; 61(6):822-5. PubMed ID: 17141740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
    Canuso CM; Singh JB; Fedgchin M; Alphs L; Lane R; Lim P; Pinter C; Hough D; Sanacora G; Manji H; Drevets WC
    Am J Psychiatry; 2018 Jul; 175(7):620-630. PubMed ID: 29656663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration.
    Evans JW; Szczepanik J; Brutsché N; Park LT; Nugent AC; Zarate CA
    Biol Psychiatry; 2018 Oct; 84(8):582-590. PubMed ID: 29580569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketamine use in current clinical practice.
    Gao M; Rejaei D; Liu H
    Acta Pharmacol Sin; 2016 Jul; 37(7):865-72. PubMed ID: 27018176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine and other glutamate receptor modulators for depression in adults.
    Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of intranasal ketamine in major depressive disorder.
    Lapidus KA; Levitch CF; Perez AM; Brallier JW; Parides MK; Soleimani L; Feder A; Iosifescu DV; Charney DS; Murrough JW
    Biol Psychiatry; 2014 Dec; 76(12):970-6. PubMed ID: 24821196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
    Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
    Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations between multimodal neuroimaging and peripheral inflammation in different subtypes and mood states of bipolar disorder: a systematic review.
    Long JY; Li B; Ding P; Mei H; Li Y
    Int J Bipolar Disord; 2024 Feb; 12(1):5. PubMed ID: 38388844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrochemical detection of the neurotransmitter glutamate and the effect of the psychotropic drug riluzole on its oxidation response.
    Yu T; Cui J; Chen S
    Anal Bioanal Chem; 2024 Mar; 416(7):1707-1716. PubMed ID: 38363306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal cord and brain concentrations of riluzole after oral and intrathecal administration: A potential new treatment route for amyotrophic lateral sclerosis.
    Keifer OP; Gutierrez J; Butt MT; Cramer SD; Bartus R; Tansey M; Deaver D; Betourne A; Boulis NM
    PLoS One; 2023; 18(8):e0277718. PubMed ID: 37607205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic Efficacy of Riluzole against Anxiety- and Depressive-Like Behaviors in Two Rodent Stress Models.
    Bansal Y; Fee C; Misquitta KA; Codeluppi SA; Sibille E; Berman RM; Coric V; Sanacora G; Banasr M
    Complex Psychiatry; 2023; 9(1-4):57-69. PubMed ID: 37101541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-Resistant Bipolar Depression: Therapeutic Trends, Challenges and Future Directions.
    Elsayed OH; Ercis M; Pahwa M; Singh B
    Neuropsychiatr Dis Treat; 2022; 18():2927-2943. PubMed ID: 36561896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-fat diet induces depression-like phenotype via astrocyte-mediated hyperactivation of ventral hippocampal glutamatergic afferents to the nucleus accumbens.
    Tsai SF; Hsu PL; Chen YW; Hossain MS; Chen PC; Tzeng SF; Chen PS; Kuo YM
    Mol Psychiatry; 2022 Nov; 27(11):4372-4384. PubMed ID: 36180573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents.
    Vasiliu O
    Front Pharmacol; 2022; 13():884155. PubMed ID: 35847011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot spectroscopy study of adversity in adolescents.
    Sonmez AI; Lewis CP; Port JD; Athreya AP; Choi DS; Zaccariello MJ; Shekunov J; Blacker CJ; Croarkin PE
    Biomark Neuropsychiatry; 2021 Dec; 5():. PubMed ID: 35783196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis.
    Bahji A; Zarate CA; Vazquez GH
    Expert Opin Drug Saf; 2022 Jun; 21(6):853-866. PubMed ID: 35231204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.